Literature DB >> 21741197

Changes in methadone maintenance therapy during and after pregnancy.

Brittany Albright1, Lesley de la Torre, Betty Skipper, Sylvia Price, Patrick Abbott, William Rayburn.   

Abstract

OBJECTIVE: The aim of this study is to better understand anticipated changes in daily methadone doses as a guide for prescription during pregnancy.
METHODS: This retrospective case series involved a single cohort longitudinal design of 139 consecutively chosen women who began methadone therapy before 26 completed gestational weeks. Changes in the single daily dose were based on a standard opiate withdrawal scale and determined from early pregnancy until 6 weeks postpartum.
RESULTS: As gestation advanced, the methadone dose increased (86%) rather than remained the same (8%) or decreased (7%). This gradual increase in daily dose during pregnancy (mean increase = 24 mg, 95% confidence level = 20-28 mg) was statistically significant (p < .001) regardless of the initial maintenance dose. By the sixth postpartum week, most subjects (85%) took within 10 mg of their dose at delivery (mean change in dose = -4 mg, 95% confidence interval = -6 to -2 mg).
CONCLUSIONS: Daily doses of methadone increased until the third trimester, then remained essentially unchanged through the sixth postpartum week.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21741197     DOI: 10.1016/j.jsat.2011.05.002

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  9 in total

Review 1.  Pharmacological Management of Opioid Use Disorder in Pregnant Women.

Authors:  Christine M Wilder; Theresa Winhusen
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

2.  Postpartum changes in methadone maintenance dose.

Authors:  Christine A Pace; Leah B Kaminetzky; Michael Winter; Debbie M Cheng; Kelley Saia; Jeffrey H Samet; Alexander Y Walley
Journal:  J Subst Abuse Treat       Date:  2014-05-02

Review 3.  The management of opioid dependence during pregnancy in rural and remote settings.

Authors:  Naana Afua Jumah; Lisa Graves; Meldon Kahan
Journal:  CMAJ       Date:  2014-10-06       Impact factor: 8.262

Review 4.  Opioid Use in Pregnancy.

Authors:  Amalia Londono Tobon; Erin Habecker; Ariadna Forray
Journal:  Curr Psychiatry Rep       Date:  2019-11-16       Impact factor: 5.285

Review 5.  Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.

Authors:  Hendrée E Jones; Sarah H Heil; Andjela Baewert; Amelia M Arria; Karol Kaltenbach; Peter R Martin; Mara G Coyle; Peter Selby; Susan M Stine; Gabriele Fischer
Journal:  Addiction       Date:  2012-11       Impact factor: 6.526

6.  Dosing and monitoring of methadone in pregnancy: literature review.

Authors:  Jennifer R Shiu; Mary H H Ensom
Journal:  Can J Hosp Pharm       Date:  2012-09

7.  Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Childhood Outcomes: Executive Summary of a Joint Workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, American College of Obstetricians and Gynecologists, American Academy of Pediatrics, Society for Maternal-Fetal Medicine, Centers for Disease Control and Prevention, and the March of Dimes Foundation.

Authors:  Uma M Reddy; Jonathan M Davis; Zhaoxia Ren; Michael F Greene
Journal:  Obstet Gynecol       Date:  2017-07       Impact factor: 7.623

8.  Pregnancy Alters CYP- and UGT-Mediated Metabolism of Buprenorphine.

Authors:  Hongfei Zhang; Jaime R Bastian; Wenchen Zhao; Huijun Chen; Imam H Shaik; Nupur Chaphekar; Steve N Caritis; Raman Venkataramanan
Journal:  Ther Drug Monit       Date:  2020-04       Impact factor: 3.118

9.  Educational achievement at age 9.5 years of children born to mothers maintained on methadone during pregnancy.

Authors:  Samantha J Lee; Lianne J Woodward; Jacqueline M T Henderson
Journal:  PLoS One       Date:  2019-10-10       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.